• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Amgen

Amgen

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. UPDATE: Cancer vaccines, long considered -2-

    UPDATE: Cancer vaccines, long considered -2-

  2. UPDATE: Cancer vaccines, long considered failures, are hot again

    UPDATE: Cancer vaccines, long considered failures, are hot again

  3. UPDATE: Cancer vaccines, long considered -2-

    UPDATE: Cancer vaccines, long considered -2-

  4. UPDATE: Cancer vaccines, long considered failures, are hot again

    UPDATE: Cancer vaccines, long considered failures, are hot again

  5. Amgen's cholesterol drug is cost-effective at $10,000 a year: study

    Amgen's cholesterol drug is cost-effective at $10,000 a year: study

  6. UPDATE: Cancer vaccines, long considered -2-

    UPDATE: Cancer vaccines, long considered -2-

  7. UPDATE: Cancer vaccines, long considered failures, are hot again

    UPDATE: Cancer vaccines, long considered failures, are hot again

  8. Cell Medica Appoints CSO to Accelerate R&D for CAR and TCR Programmes

    Cell Medica Appoints CSO to Accelerate R&D for CAR and TCR Programmes

  9. Global Biosimilars Market Growth, Trends & Forecasts 2017-2022 - Research and Markets

    Global Biosimilars Market Growth, Trends & Forecasts 2017-2022 - Research and Markets

12345

©2017 Morningstar Advisor. All right reserved.